145 related articles for article (PubMed ID: 35634603)
1. Effects of carboplatin combined with paclitaxel-based intraperitoneal hyperthermic perfusion chemotherapy on serum levels of HE4 and DJ-1 in patients with advanced recurrent ovarian cancer.
Su X; Sun X; Kang Y; Dai Y
Pak J Med Sci; 2022; 38(4Part-II):872-877. PubMed ID: 35634603
[TBL] [Abstract][Full Text] [Related]
2. Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer.
Tan X; Zou S; Chen H; Chen D
J Int Med Res; 2023 Sep; 51(9):3000605231200267. PubMed ID: 37756606
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of bevacizumab combined with nedaplatin in the treatment of ovarian cancer and its effects on tumor markers and immunity of patients.
Zhang H; Chen C; Wang S; Li X; Fan T
J BUON; 2020; 25(1):80-86. PubMed ID: 32277617
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy analysis of Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with Paclitaxel-Cisplatin Chemotherapy in patients with Advanced Ovarian Cancer.
Gao Y; Hao Y; Jia Y
J BUON; 2021; 26(2):553-560. PubMed ID: 34077005
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the short-term efficacy and serum markers between lobaplatin/paclitaxel- And carboplatin/paclitaxel-based adjuvant chemotherapy in patient with ovarian cancer.
Wang W; Liu M; Ding B
J Clin Pharm Ther; 2021 Feb; 46(1):166-172. PubMed ID: 33098169
[TBL] [Abstract][Full Text] [Related]
6. Clinical effects of TP-based hyperthermic intraperitoneal chemotherapy (HIPEC) on CD133 and HE4 expression in advanced epithelial ovarian cancer.
Su X; Sun X; Wang Y; Kang Y; Dai Y
Pak J Med Sci; 2022; 38(6):1508-1513. PubMed ID: 35991244
[TBL] [Abstract][Full Text] [Related]
7. Olaparib and paclitaxel in combination with carboplatin in treatment of ovarian cancer: influence on disease control.
Zhang H; Zhang Y
Am J Transl Res; 2022; 14(1):468-475. PubMed ID: 35173866
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of neoadjuvant chemotherapy combined with intraperitoneal hyperthermic chemotherapy in advanced ovarian cancer.
Xu Z; Ge X; Zhang T; Shi Y; Sun M
J BUON; 2020; 25(2):772-778. PubMed ID: 32521866
[TBL] [Abstract][Full Text] [Related]
9. A Novel Model to Prevent Venous Thromboembolism in Patients with Lung Cancer.
Wu X; Lin B; Zhu H
Altern Ther Health Med; 2024 Mar; 30(3):146-151. PubMed ID: 37883756
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Value of Serum Markers Combined with TVCDS in Ovarian Cancer Patients Treated with Bushen Yiqi Quyu Prescription.
Qin W; Jiang F; Zhang T
Evid Based Complement Alternat Med; 2021; 2021():3522906. PubMed ID: 34917157
[TBL] [Abstract][Full Text] [Related]
11. Clinical Efficacy of Yiqi Yangyin Decoction Combined with Docetaxel on Advanced Ovarian Cancer and the Effect on the Levels of Serum Markers VEGF, HE4, and CA125.
Wang N; Xiao F; Shao H; Shi S; Zhou Y
J Healthc Eng; 2022; 2022():8401202. PubMed ID: 35368946
[TBL] [Abstract][Full Text] [Related]
12. Comparisons of efficacy and safety between docetaxel + cisplatin and paclitaxel + cisplatin and their effects on serum HE4, CA125 and ROMA indicators in patients with ovarian carcinoma.
Han L; Kuang L
J BUON; 2019; 24(4):1544-1548. PubMed ID: 31646806
[TBL] [Abstract][Full Text] [Related]
13. Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer.
Jiang YL; Fu XY; Yin ZH
World J Gastrointest Surg; 2023 May; 15(5):906-916. PubMed ID: 37342840
[TBL] [Abstract][Full Text] [Related]
14. Effects on the immune system and toxicity of carboplatin/paclitaxel combination chemotherapy in patients with stage III-IV ovarian and non small cell lung cancer and its role in survival and toxicity.
Hatziveis K; Tourlakis D; Hountis P; Kyriazanos I; Sougleri M; Ginopoulos P; Camoutsis C
J BUON; 2012; 17(1):143-8. PubMed ID: 22517709
[TBL] [Abstract][Full Text] [Related]
15. Effect of glutamine on the immune function of paclitaxel intervention in ovarian cancer mice.
Wang L; Li Y; Wang J
Cell Mol Biol (Noisy-le-grand); 2020 May; 66(2):193-197. PubMed ID: 32415947
[TBL] [Abstract][Full Text] [Related]
16. The research on the influences of hyperthermal perfusion chemotherapy combined with immunologic therapy on the immunologic function and levels of circulating tumor cells of the advanced colorectal cancer patients with liver metastasis.
Sun JJ; Fan GL; Wang XG; Xu K
Eur Rev Med Pharmacol Sci; 2017 Jul; 21(13):3139-3145. PubMed ID: 28742190
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of highly agglutinative staphylococcin combined with neoadjuvant chemotherapy on patients with intermediate or advanced oral cancer.
Guo N; Lin G; Shi X
Pak J Med Sci; 2022; 38(7):1973-1979. PubMed ID: 36246715
[TBL] [Abstract][Full Text] [Related]
18. Clinical effects of Chemotherapy combined with Immunotherapy in patients with advanced NSCLC and the effect on their nutritional status and immune function.
Jiao J; Li WW; Shang YH; Li XF; Jiao M
Pak J Med Sci; 2023; 39(2):404-408. PubMed ID: 36950407
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.
Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Int J Gynecol Cancer; 2011 Aug; 21(6):1040-7. PubMed ID: 21738039
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin.
Tao Y; Tang XT; Li X; Wu AS; Zhou HS; Zhou CF
Front Med (Lausanne); 2022; 9():807377. PubMed ID: 35355595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
